Exelixis Inc. Common Stock vs Liberty Media Corporation Series C Liberty Formula One Common Stock — how do they compare? Exelixis Inc. Common Stock trades at $60.95 (market cap $14.75B), while Liberty Media Corporation Series C Liberty Formula One Common Stock trades at $90.85 (market cap $23.11B). The key difference: Liberty Media Corporation Series C Liberty Formula One Common Stock is the larger of the two by market cap, and Exelixis Inc. Common Stock is trading nearer its 52-week high, Liberty Media Corporation Series C Liberty Formula One Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Exelixis Inc. Common Stock for 3 Days and Liberty Media Corporation Series C Liberty Formula One Common Stock for 0 Days on average.
| EXEL | FWONK | |
|---|---|---|
Market Cap | $14.75B | $23.11B |
Volume | 2,624,658 | 3,394,596 |
Sector | Health | Media |
52-Week High | $60.99 | $106.66 |
52-Week Low | $34.54 | $81.42 |
Typical Hold Time | 3 Days | 0 Days |
Enterprise Value | $14.07B | $26.57B |
Signals from Pluang's Aura AI — not financial advice
EXEL trades at $59.51, down 0.52% on the day but near its 52-week high of $61.66 reached on October 12, 2026. The stock shows strong technical momentum with bullish moving averages and has consistently beaten earnings estimates in recent quarters. Recent news highlights include a three-month FDA review delay for zanzalintinib but continued growth in CABOMETYX revenue, which surpassed $3 billion annually.
The outlook remains positive with strong profitability metrics (35.33% net margin, 44.39% ROE) and projected revenue growth to $2.4 billion in 2026. Key risks include regulatory delays for new drug approvals and competitive pressures in oncology. Analyst consensus is mixed with 48% buy ratings but a price target of $52.33 suggesting potential downside from current levels.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Exelixis develops and commercializes medicines for cancer. Its research focuses on targeted therapies for oncology.
Read more on EXEL →Liberty Media Corporation's Series C Liberty Formula One common stock is a tracking stock reflecting the economic performance of the Formula One Group, which holds Liberty Media's interests in Formula 1 racing, MotoGP, and related minority investments.
Read more on FWONK →